Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Roach E, Laplante S, Stogryn S et al (2023) Weight loss outcomes for patients undergoing conversion to Roux-en-Y-gastric bypass after sleeve gastrectomy
One is Virta Health, which advertises its nutrition-focused weight management program as a proven approach for deprescribing GLP-1s when clinically appropriate. A Virta-funded study assessed 154 people with Type 2 diabetes who stopped using GLP-1 medications but continued following Virtas program, concluding that their weight did not significantly increase after a year
Regular follow-ups occur monthly during initial treatment phases, then every 2-3 months once stable
Common adverse effects are predominantly gastrointestinal and typically emerge during dose escalation: Nausea (affecting 2050% of users initially) Vomiting and diarrhoea Constipation Abdominal pain and bloating Reduced appetite (therapeutic effect but may be excessive) Fatigue and headache Injection site reactions (redness, swelling or itching) These effects usually diminish over several weeks as the body adjusts
While you cannot speed up the digestion process significantly, you can support your body as it works through the meal
